Selected research
Industry Research
Gastric Mucosal Protective Drug Industry Research Report 2026
Market perspective
The global Gastric Mucosal Protective Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Gastric Mucosal Protective Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Gastric Mucosal Protective Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Gastric Mucosal Protective Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Gastric Mucosal Protective Drug include Zhejaing Yuanlijian, Eisai Co., Teva, LIVZON, Guangdong Huanan Pharma, Bayer, AbbVie, Viatris and Otsuka Pharmaceutical, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Gastric Mucosal Protective Drug market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Gastric Mucosal Protective Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Gastric Mucosal Protective Drug Market by Company
Zhejaing Yuanlijian
Eisai Co.
Teva
LIVZON
Guangdong Huanan Pharma
Bayer
AbbVie
Viatris
Otsuka Pharmaceutical
Nostrum Pharmaceuticals
Endo International
Astellas Pharma
Amneal Pharmaceuticals
Gastric Mucosal Protective Drug Segment by Type
Rebamipide
Sucralfate
Bismuth Potassium Citrate
Other
Gastric Mucosal Protective Drug Segment by Application
Hospital
Retail Pharmacy
Other
Gastric Mucosal Protective Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastric Mucosal Protective Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gastric Mucosal Protective Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastric Mucosal Protective Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Gastric Mucosal Protective Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Rebamipide
- Sucralfate
- Bismuth Potassium Citrate
- Other
Applications
- Hospital
- Retail Pharmacy
- Other
Companies covered
- Zhejaing Yuanlijian
- Eisai Co.
- Teva
- LIVZON
- Guangdong Huanan Pharma
- Bayer
- AbbVie
- Viatris
- Otsuka Pharmaceutical
- Nostrum Pharmaceuticals
- Endo International
- Astellas Pharma
- Amneal Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Gastric Mucosal Protective Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Rebamipide
- 2.2.3 Sucralfate
- 2.2.4 Bismuth Potassium Citrate
- 2.2.5 Other
- 2.3 Gastric Mucosal Protective Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Retail Pharmacy
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Gastric Mucosal Protective Drug Breakdown Data by Type
- 3.1 Global Gastric Mucosal Protective Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Gastric Mucosal Protective Drug Forecasted Market Size by Type (2027-2032)
4 Gastric Mucosal Protective Drug Breakdown Data by Application
- 4.1 Global Gastric Mucosal Protective Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Gastric Mucosal Protective Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Gastric Mucosal Protective Drug Market Perspective (2021-2032)
- 5.2 Global Gastric Mucosal Protective Drug Growth Trends by Region
- 5.2.1 Global Gastric Mucosal Protective Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Gastric Mucosal Protective Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Gastric Mucosal Protective Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Gastric Mucosal Protective Drug Market Dynamics
- 5.3.1 Gastric Mucosal Protective Drug Industry Trends
- 5.3.2 Gastric Mucosal Protective Drug Market Drivers
- 5.3.3 Gastric Mucosal Protective Drug Market Challenges
- 5.3.4 Gastric Mucosal Protective Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Gastric Mucosal Protective Drug Players by Revenue
- 6.1.1 Global Top Gastric Mucosal Protective Drug Players by Revenue (2021-2026)
- 6.1.2 Global Gastric Mucosal Protective Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Gastric Mucosal Protective Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Gastric Mucosal Protective Drug Head Office and Area Served
- 6.4 Global Gastric Mucosal Protective Drug Players, Product Type & Application
- 6.5 Global Gastric Mucosal Protective Drug Manufacturers Established Date
- 6.6 Global Gastric Mucosal Protective Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Gastric Mucosal Protective Drug Market Size (2021-2032)
- 7.2 North America Gastric Mucosal Protective Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Gastric Mucosal Protective Drug Market Size by Country (2021-2026)
- 7.4 North America Gastric Mucosal Protective Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Gastric Mucosal Protective Drug Market Size (2021-2032)
- 8.2 Europe Gastric Mucosal Protective Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Gastric Mucosal Protective Drug Market Size by Country (2021-2026)
- 8.4 Europe Gastric Mucosal Protective Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Gastric Mucosal Protective Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Gastric Mucosal Protective Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Gastric Mucosal Protective Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Gastric Mucosal Protective Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Gastric Mucosal Protective Drug Market Size (2021-2032)
- 10.2 South America Gastric Mucosal Protective Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Gastric Mucosal Protective Drug Market Size by Country (2021-2026)
- 10.4 South America Gastric Mucosal Protective Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Gastric Mucosal Protective Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Gastric Mucosal Protective Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Gastric Mucosal Protective Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Gastric Mucosal Protective Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Zhejaing Yuanlijian
- 12.1.1 Zhejaing Yuanlijian Company Information
- 12.1.2 Zhejaing Yuanlijian Business Overview
- 12.1.3 Zhejaing Yuanlijian Revenue in Gastric Mucosal Protective Drug Business (2021-2026)
- 12.1.4 Zhejaing Yuanlijian Gastric Mucosal Protective Drug Product Portfolio
- 12.1.5 Zhejaing Yuanlijian Recent Developments
- 12.2 Eisai Co.
- 12.2.1 Eisai Co. Company Information
- 12.2.2 Eisai Co. Business Overview
- 12.2.3 Eisai Co. Revenue in Gastric Mucosal Protective Drug Business (2021-2026)
- 12.2.4 Eisai Co. Gastric Mucosal Protective Drug Product Portfolio
- 12.2.5 Eisai Co. Recent Developments
- 12.3 Teva
- 12.3.1 Teva Company Information
- 12.3.2 Teva Business Overview
- 12.3.3 Teva Revenue in Gastric Mucosal Protective Drug Business (2021-2026)
- 12.3.4 Teva Gastric Mucosal Protective Drug Product Portfolio
- 12.3.5 Teva Recent Developments
- 12.4 LIVZON
- 12.4.1 LIVZON Company Information
- 12.4.2 LIVZON Business Overview
- 12.4.3 LIVZON Revenue in Gastric Mucosal Protective Drug Business (2021-2026)
- 12.4.4 LIVZON Gastric Mucosal Protective Drug Product Portfolio
- 12.4.5 LIVZON Recent Developments
- 12.5 Guangdong Huanan Pharma
- 12.5.1 Guangdong Huanan Pharma Company Information
- 12.5.2 Guangdong Huanan Pharma Business Overview
- 12.5.3 Guangdong Huanan Pharma Revenue in Gastric Mucosal Protective Drug Business (2021-2026)
- 12.5.4 Guangdong Huanan Pharma Gastric Mucosal Protective Drug Product Portfolio
- 12.5.5 Guangdong Huanan Pharma Recent Developments
- 12.6 Bayer
- 12.6.1 Bayer Company Information
- 12.6.2 Bayer Business Overview
- 12.6.3 Bayer Revenue in Gastric Mucosal Protective Drug Business (2021-2026)
- 12.6.4 Bayer Gastric Mucosal Protective Drug Product Portfolio
- 12.6.5 Bayer Recent Developments
- 12.7 AbbVie
- 12.7.1 AbbVie Company Information
- 12.7.2 AbbVie Business Overview
- 12.7.3 AbbVie Revenue in Gastric Mucosal Protective Drug Business (2021-2026)
- 12.7.4 AbbVie Gastric Mucosal Protective Drug Product Portfolio
- 12.7.5 AbbVie Recent Developments
- 12.8 Viatris
- 12.8.1 Viatris Company Information
- 12.8.2 Viatris Business Overview
- 12.8.3 Viatris Revenue in Gastric Mucosal Protective Drug Business (2021-2026)
- 12.8.4 Viatris Gastric Mucosal Protective Drug Product Portfolio
- 12.8.5 Viatris Recent Developments
- 12.9 Otsuka Pharmaceutical
- 12.9.1 Otsuka Pharmaceutical Company Information
- 12.9.2 Otsuka Pharmaceutical Business Overview
- 12.9.3 Otsuka Pharmaceutical Revenue in Gastric Mucosal Protective Drug Business (2021-2026)
- 12.9.4 Otsuka Pharmaceutical Gastric Mucosal Protective Drug Product Portfolio
- 12.9.5 Otsuka Pharmaceutical Recent Developments
- 12.10 Nostrum Pharmaceuticals
- 12.10.1 Nostrum Pharmaceuticals Company Information
- 12.10.2 Nostrum Pharmaceuticals Business Overview
- 12.10.3 Nostrum Pharmaceuticals Revenue in Gastric Mucosal Protective Drug Business (2021-2026)
- 12.10.4 Nostrum Pharmaceuticals Gastric Mucosal Protective Drug Product Portfolio
- 12.10.5 Nostrum Pharmaceuticals Recent Developments
- 12.11 Endo International
- 12.11.1 Endo International Company Information
- 12.11.2 Endo International Business Overview
- 12.11.3 Endo International Revenue in Gastric Mucosal Protective Drug Business (2021-2026)
- 12.11.4 Endo International Gastric Mucosal Protective Drug Product Portfolio
- 12.11.5 Endo International Recent Developments
- 12.12 Astellas Pharma
- 12.12.1 Astellas Pharma Company Information
- 12.12.2 Astellas Pharma Business Overview
- 12.12.3 Astellas Pharma Revenue in Gastric Mucosal Protective Drug Business (2021-2026)
- 12.12.4 Astellas Pharma Gastric Mucosal Protective Drug Product Portfolio
- 12.12.5 Astellas Pharma Recent Developments
- 12.13 Amneal Pharmaceuticals
- 12.13.1 Amneal Pharmaceuticals Company Information
- 12.13.2 Amneal Pharmaceuticals Business Overview
- 12.13.3 Amneal Pharmaceuticals Revenue in Gastric Mucosal Protective Drug Business (2021-2026)
- 12.13.4 Amneal Pharmaceuticals Gastric Mucosal Protective Drug Product Portfolio
- 12.13.5 Amneal Pharmaceuticals Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst